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Microneutralization of Cytomegalovirus
Hans Stalder and Alice Ehrensberger From the Infectious Disease Division, Department of
Internal Medicine, University of Geneva, Switzerland
A simple microneutralization test for cytomegalovirus (CMV) is presented. Using a
laboratory adapted stock virus, definite results were obtained after 10 days. All patients
with primary CMV infection showed an antibody rise and/or seroconversion; however,
neutralizing antibody appeared only seven weeks after the onset of clinical symptoms.
In control patients without evidence of recent primary infection, there was a complete
concordance of the presence of complement-fixing and neutralizing antibodies.
Neutralization tests [1-5] with cytomegalovirus
(CMV) have not been very popular because CMV
is a slow-growing virus and not easy to obtain as
high titered, cell-free virus. However, the deter-
mination of neutralizing antibodies may be more
significant in clinical situations than, for example,
levels of CF antibodies. This situation is especially
true when we seek to evaluate the responses of in-
dividuals to natural infection or CMV vaccines.
Furthermore, neutralization tests, as has been
shown for herpes simplex viruses (HSV) [6, 7], can
permit us to define and identify viral subtypes.
This paper describes the adoption to CMV of a
simple microneutralization test [7] which has prov-
en its value for typing HSV isolates and antisera.
Materials and Methods
Cells. Diploid human fibroblast cells derived
from newborn foreskin (FS-9; initiated at the
Center of Disease Control, Atlanta, Ga.) were
used. These cells were propagated as described
previously [7].
Virus. CMV (strain 268a) was originally iso-
lated from the urine of a kidney transplant recipi-
ent. The original isolate was characterized as
CMV by its focal, slowly progressing CPE, with
eosinophilic intranuclear and rare cytoplasmic in-
clusions as well as mononuclear giant cells after
staining with hematoxylin and eosin. The virus
was identified as CMV by the immunofluorescence
technique using a highly specific human antiserum
(performed by Dr. U. Krech, Institut fur Medizi-
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nische Mikrobiologie, S1. Gall, Switzerland). Fur-
thermore, specific rabbit antisera containing a
high titer of antibody to HSV type 1 (HSV-1) and
HSV type 2 (HSV-2) did not neutralize the agent
(see below).
The original isolate was passaged 16 times by
cell scraping. After the 16th passage, the cell
monolayer was trypsinized (O.04OJo trypsin and
0.54 mM EDTA) when rv80OJo of the cells showed
CPE. After centrifugation at 120 g for 10 min, the
cells were resuspended in distilled water and soni-
cated (Sonifer B-12; Branson Sonic Power Com-
pany, New Haven, Conn.) at a force of 2 for 22
sec. Microscopic examination showed almost
complete cell disruption.
This suspension was clarified at 1,()()() g for 15
min, and sorbitol was added to a final concentra-
tion of 1OOJo. The virus was aliquoted into ampules
and stored at -80 C. From this pool one ampule
was added to a 500-ml roller bottle containing a
complete cell monolayer. When rv80% of the cells
showed CPE, the culture was trypsinized, and the
cells were added to confluent monolayer cultures
in four 2,()()()-ml Roux bottles (Muller and Krem-
pel, Carouge, Switzerland). When rv80% of the
cells showed CPE, the cultures were trypsinized
and sonicated, and the clarified supernatant was
stored in 10% sorbitol at -80 C. This virus was
used for all experiments.
Microtitration and microneutralization tech-
nique. A procedure similar to that described for
HSV was used [7]. For titration of virus, 10-fold
dilutions of virus were prepared in growth medi-
um (Dulbecco's medium, supplemented with bi-
carbonate and antibiotics [7] and 10% heat-inacti-
vated [56 C for 30 min] fetal calf serum). Then
0.05 ml of each dilution of virus was placed in
each of six wells of sterile, disposable microtest
culture plates with 96 flat-bottom wells
(M29ART, Microtiter system; Cooke Engineer-
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ing, Alexandria, Va.). Immediately, 0.05 ml of a
cell suspension containing 200,000 cells/ml in
growth medium was added. The plates were cov-
ered and incubated at 36 C in a moist atmosphere
of 50,10 CO2 in air. The CPE was read using an in-
verted microscope. All wells were scored as +
(CPE present) or - (no CPE), and end-point dilu-
tion titers were calculated using the Karber meth-
od [8].
For serum neutralization studies, twofold dilu-
tions were prepared in growth medium. First,
0.025 ml of each dilution was placed in three repli-
cate wells. Then, 0.025 ml of viral suspension con-
taining rv200 TCIDso/0.05 ml was added to two of
the three wells. The remaining well received 0.025
ml of growth medium (serum control). Then,
0.025 ml of a 1:4 or 1:8 dilution of either fresh or
heat-inactivated (56 C for 30 min) guinea pig se-
rum (stored at -80 C) was added to all of the
wells. The plates were then incubated at different
temperatures for various intervals (see Results).
Finally, 0.05 ml of the cell suspension was added,
and the plates were incubated in the CO 2 incubator
for various intervals (see Results).
When plates were read at 10 days, a change of
medium was not necessary. The results were read
as described above, and serum titers were ex-
pressed as the reciprocals of the highest dilution of
serum that inhibited viral CPE.
CF tests [9] and determination of CMV-specific
IgM antibody (10] were performed by Dr. U.
Krech using the Davis strain of CMV as the anti-
gen.
Results
Titration of virus. Viral titers were between
log 2.66 and log 3.83 TCIDso/0.05 ml. Exposure of
the diluted virus to different temperatures before
addition of cells appeared to modify the course of
infection. When the virus was held for 30-120 min
at 4 C before it was placed into the wells of the mi-
crotest plates, the subsequent development of
CPE was delayed, so that at 10 days, the virus held
at 4 C appeared to have a titer 1 log lower than the
same virus held at 22 C or 37 C. However, CPE
eventually developed so that after 18 days of incu-
bation, the final titers were comparable. Addition
of either fresh or heat-inactivated guinea pig serum
did not change the kinetics of CPE development
or the final titer of virus.
Serum neutralization. No consistent differ-
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ence of neutralizing titer was observed when mix-
ing periods of virus and serum were varied (30, 60,
and 120 min) or when mixing was done at different
temperatures (4, 22, and 37 C). Therefore mixing
was done at 37 C for 30 min in all further experi-
ments. Since reading the test after 15, rather 10,
days of incubation changed in titers very little (on-
ly, and that inconstantly, about half a dilution
lower at 15 days), all tests were read at 10 days.
Fresh guinea pig serum increased the titers up to
l l-fold (mean, fourfold) (table 1). Several sera
were positive only after addition of fresh guinea
pig serum.
Patient sera. Sequential sera from 11 patients
who appeared on clinical and virologic grounds to
have primary CMV infection were examined.
CMV was isolated from all except one patient, and
all developed either CMV-specific fluorescent IgM
antibody or a fourfold rise in CF antibody titer
(tests performed by Dr. U. Krech). No serum con-
tained detectable neutralizing antibodies earlier
than seven weeks after the beginning of the illness.
After 10 weeks, however, multiple sera from all
patients were positive. Seroconversion was docu-
mented in eight patients (table 1 and figure 1).
Ten sera from unpaid blood donors and 10 sera
containing CF antibodies to HSV from patients
from whom HSV was isolated were tested. Five of
each group had positive titers of neutralizing an-
tibody to CMV. Their values were compared with
titers of CF antibody to CMV. No serum that
lacked neutralizing antibody gave a positive CF
test and vice versa.
Discussion
Using the microneutralization technique, we
demonstrated the appearance of neutralizing an-
tibodies in the sera of all patients suspected of
having primary CMV infection, when tested 10
weeks or later after the onset of clinical symp-
toms. However, none was positive before seven
weeks. Late appearance of neutralizing, in con-
trast to CF or fluorescent, antibodies has already
been noted by Spencer and Andersen [11]. Al-
though not tested in our laboratory, it is possible
that early IgM antibodies have little neutralizing
activity [12]. The clinical implication of this is not
clear, but it is interesting to note that the clinical
course as well as viral excretion in CMV infections
is protracted. In our test system, addition of fresh
guinea pig serum enhanced neutralizing antibody
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Table 1. Enhancement of serum neutralization titers by addition of fresh guinea pig serum in patients with clinical-
ly suspected primary infection with cytomegalovirus (CMV).
Reciprocal titer of Reciprocal neutralization titer
Weeks after
antibody with guinea pig serum
beginning CMV -specific Heat-
Patient no. of illness IgM CF Fresh inactivated
1 NO <10 NO NO
4 320 40 <5 <5
15 NO NO 10 <5
2 2 640 80 NO NO
5 320 240 <5 <5
16 20 240 120 10
57 NO NO 30 10
3 9 80 240 10 <5
58 NO NO 160 20
4 3 320 30 NO NO
4 NO 120 <5 <5
23 20 NO 20 10
5 1 5 <10 <5 <5
9 20 240 5 <5
6 5 80 ~160 <5 <5
23 NO NO 20 15
76 <5 ~160 40 15
90 NO 120 20 10
7 13 40 ~160 20 10
16 10 ~160 15 <5
30 NO NO 15 <5
8 2 80 240 <5 <5
6 40 240 <5 <5
9 3 NO NO <5 <5
8 80 240 <5 <5
25 <5 240 15 <5
10 12 20 128 NO 15
58 NO NO 120 60
11 2 NO 10 <5 <5
7 NO ~160 10 <5
NOTE. NO = not done.
titers about fourfold, presumably due to the ac-
tion of complement. Several sera became positive
only after addition of fresh guinea pig serum. Its
addition is therefore mandatory when this tech-
nique is used.
Complement enhancement is not unique to
neutralization of CMV but has also been noted
with other viruses, especially those of the herpes
group [13, 14]. However, complement enhance-
ment of human sera has been found irregularly in
CMV plaque-neutralization assays [5, 12, I5}.
This observation is in contrast to those with
animal sera, some of which are completely depen-
dent on complement for neutralizing activity [3,
12]. There was a complete correlation between the
microneutralization test and the CF test in twenty
control patients. No patient with a negative titer in
one test had a positive one in the other.
This microneutralization technique [7] has
several advantages over other neutralization tests;
for example, transfer of virus-serum mixtures is
avoided because the cells are added to the same
well. Owing to the microtechnique, only small
amounts of serum (0.025 ml for each serum dilu-
tion), of virus, and of cells, are necessary. It is
therefore easy to test multiple sera in the same
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test, and furthermore, the test can be performed in
multiple duplicates, eventually permitting subtyp-
ing of CMV isolates [16]. Indeed, a similar test
was originally used to detect subtypes of .HSV
isolates [6]. Finally, the test can be performed at
room temperature or at 37 C. The peculiar effect
of preincubation of dilutions of virus at 4 C on
reducing the subsequent development of CPE is
unexplained. While it may simply be some reversi-
ble physical phenomenon such as aggregation, it
may also be related to the resistance of CMV to
elevated temperatures which has been noted by
Vonka and Benyesh-Melnick [17].
Figure 1. Development of neutralizing antibodies in
patients with suspected primary cytomegalovirus infec-
tion.
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